机构:[1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing Engineering Research Center for Nervous System Drugs, Beijing Institute for Brain Disorders, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 100053, China科技平台神经变性病教育部重点实验室首都医科大学宣武医院
Beijing Postdoctoral Research Foundation (2018-ZZ-105), Postdoctoral Science Foundation of China (2019M650776), Beijing Hospitals Authority Youth Programme (QMS20200811), Capital Science and Technology Leading Talent Training Project (Z191100006119017), and Beijing Hospitals Authority Ascent Plan (DFL20190803).
第一作者机构:[1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing Engineering Research Center for Nervous System Drugs, Beijing Institute for Brain Disorders, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 100053, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing Engineering Research Center for Nervous System Drugs, Beijing Institute for Brain Disorders, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 100053, China[*1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, 45 Chang-chun Street, Beijing 100053, China
推荐引用方式(GB/T 7714):
Yang Cuicui,Gong Shili,Chen Xiaoping,et al.Analgecine regulates microglia polarization in ischemic stroke by inhibiting NF-κB through the TLR4 MyD88 pathway.[J].INTERNATIONAL IMMUNOPHARMACOLOGY.2021,99:107930.doi:10.1016/j.intimp.2021.107930.
APA:
Yang Cuicui,Gong Shili,Chen Xiaoping,Wang Mingyang,Zhang Li...&Hu Chaoying.(2021).Analgecine regulates microglia polarization in ischemic stroke by inhibiting NF-κB through the TLR4 MyD88 pathway..INTERNATIONAL IMMUNOPHARMACOLOGY,99,
MLA:
Yang Cuicui,et al."Analgecine regulates microglia polarization in ischemic stroke by inhibiting NF-κB through the TLR4 MyD88 pathway.".INTERNATIONAL IMMUNOPHARMACOLOGY 99.(2021):107930